Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affects the antitumor activity of doxorubicin.

S.A.B.E. van Acker, E. Boven, K. Kuiper, D.J. van den Berg, J.A. Grimbergen, K. Kramer, A. Bast, W.J.F. van der Vijgh

    Research output: Contribution to JournalArticleAcademicpeer-review

    Original languageEnglish
    Pages (from-to)1747-1754
    JournalClinical Cancer Research
    Volume3
    Publication statusPublished - 1997

    Cite this